curasan AG broadens orthobiologic portfolio with the launch of CERASORB® CPC (Calcium Phosphate Cement) bone void fillers.

 curasan AG (Frankfurt, Germany), a pioneer and leading global provider of biomaterials for bone and tissue regeneration in dental and orthobiologic indications, broadens its product portfolio with CERASORB® CPC (Calcium Phosphate Cement) Bone Void Fillers for maxillofacial, orthopedic and trauma surgery.

Bone augmentation and regeneration in maxillofacial, orthopedic and trauma surgery for surgical reconstructions remains a challenge. Where natural healing processes are insufficient, enhanced bone augmentation by means of biomimetic scaffolds is needed. Existing concepts for structural and functional repair of lost bone, e. g. after trauma, infections, tumor resections, or due to skeletal abnormalities are widespread, but have limitations and often result in additional bottlenecks for patients, surgeons and the healthcare systems alike.

“By adding the ready-to-use, sterile packed, self-setting bone void filler CERASORB® CPC to curasan’s orthobiologic portfolio, we are closing an important therapy gap, by offering patients, surgeons, OR staff and healthcare providers alike a unique, time- and cost-saving as well as clinically proven and effective solution for a large number of yet unmet challenges in orthopedic-, trauma- and maxillofacial surgery”, states Dirk Dembski, CEO of curasan AG. “Following our legacy as pioneers in biosurgery, we will offer this product innovation in Europe first, followed by an extended launch in other regions of the world. We look forward to living up our pioneering role in the orthobiologic market and onboarding new distribution partners for our product portfolio, that will be further broadened with disruptive products in the upcoming months”, he continues. 

Empowering fracture healing with CERASORB® CPC

CERASORB® CPC is a synthetic, biocompatible, osteoconductive and bioresorbable mineral bone cement composed of calcium and phosphate salts finely dispersed in a biocompatible oil phase made from plant-based raw materials and emulsifiers for filling non-load-bearing and non-infected bone defects.

The setting reaction of CERASORB® CPC starts directly after application in an aqueous surgical environment, and then sets in situ to a microcrystalline, calcium-deficient hydroxyapatite (CDHA) and alpha-tricalcium phosphate. The chemical composition and crystalline structure of the final reaction product (CDHA) correspond largely to the mineral components of natural bone. Furthermore, CERASORB® CPC does not contain any substances of animal origin, added preservatives or pharmacologically active agents. The surface dimensional stability of CERASORB® CPC starts after 10 to 15 minutes and reaches a compressive strength of up to 45 MPa in a fully hardened state after several days. CERASORB® CPC is designed for use in open and minimally invasive applications, thus can be applied directly to the bone defect from the syringe or with a cannula without any further preparation.

Read me....

Comments

Post a Comment

Popular posts from this blog

Medtronic announces first procedure in Europe with Hugo™ robotic-assisted surgery system

Robotic prostatectomy performed by Doctor Alexandre Mottrie at Onze-Lieve-Vrouw Ziekenhuis (OLV) in Aalst, Belgium DUBLIN and AALST, Belgium, Feb. 2, 2022 /PRNewswire(opens new window)/ --Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and OLV Hospital Aalst today announced that the first clinical procedure in Europe was performed with the Hugo™ robotic-assisted surgery (RAS) system. The robotic prostatectomy was performed by Prof. Alexandre Mottrie, M.D., head of urology at OLV Hospital in Aalst, Belgium, and chief executive officer and founder of the Belgium-based ORSI Academy, a multidisciplinary center for training, research and development, and data analysis to improve minimally invasive surgery best practices. "Performing Europe's very first procedure with the Hugo RAS system is a career highlight for me," said Dr. Mottrie. "With more than two decades and 4,000 robotic-assisted surgery proced...
Read more

European Union Green Lights PD-L1 Companion Diagnostic for Adjuvant Atezolizumab in NSCLC

CE label expansion was granted to the Ventana PD-L1 (SP263) assay for use as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) who are eligible for treatment with adjuvant atezolizumab (Tecentriq). 1 “With early detection of lung cancer, it is possible to give patients more treatment options and potentially improve a patient's outcome,” Jill German, head of Pathology Lab at Roche Diagnostics, said in a press release. “We are proud to offer a PD-L1 test that may qualify lung cancer patients for [atezolizumab] therapy. With this latest expansion, clinicians can consider multiple targeted immunotherapy options with one test to quickly determine the right treatment for each patient.” On June 14, 2022, the  European Commission approved atezolizumab  for use as adjuvant therapy following complete resection and platinum-based chemotherapy in adult patients with NSCLC at high risk of recurrence whose tumors do not have  EGFR  mutations or...
Read more